Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2025Current Opinion in Hematology

Mesenchymal stromal cells: an update

View Full Paper
Ask AI
Bookmark
Share

Authors

OLOlivia J. LeeAKArmand Keating

Discussion

Loading...

Member takes

Overview

Review discusses immunomodulatory mechanisms and clinical trials of mesenchymal stromal cells, suggesting new opportunities for treatment.

Key Points

  • MSCs are involved in over 1500 clinical trials, including promising results for Covid-19-associated ARDS.
  • Recent findings highlight the role of microRNAs and long noncoding RNAs in MSC immunomodulation.
  • Single-cell analyses reveal MSC heterogeneity, presenting challenges for standardizing potency in therapies.
  • FDA's updated potency assay recommendations emphasize the need for universal standards to improve clinical outcomes.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/689a02c9e6551bb0af8ccd68https://doi.org/10.1097/moh.0000000000000887
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Next-generation approaches for mesenchymal stem cell characterization and therapeutic application2025 · 1 citations
  2. 2Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects: Update from 2015 review2024 · 13 citations
  3. 3From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence2025 · 44 citations
  4. 4Mesenchymal Stem/Stromal Cells: A Review for Its Use After Allogeneic Hematopoietic Stem Cell Transplantation2026 · 1 citations
  5. 5An overview of Mesenchymal stromal cells: biology, functional role and therapeutic potential2026